Thanks to our Australian collaborators, NHMRC National Institute for Dementia Research and Dementia Australia.

Sydney, Australia
Sept. 25-27, 2019
Hyatt Regency Sydney

Wednesday, Sept. 25

8-9 a.m.  Rolling registration and breakfast

9-9:25 a.m.  Welcome Address
Alzheimer’s Association
Dementia Australia
National Institute for Dementia Research

Harry Johns (U.S.)
Maree McCabe (AUS)
Roberta Redman (AUS)
Janice Besch (AUS)

9:25-9:55 a.m.  Keynote
Molecular Imaging of Dementia:
Research and Clinical Application

Christopher Rowe (AUS)

Session 1: Novel Biomarkers: Volume 1
Session Leader: Donna Wilcock (U.S.)

9:55-10:15 a.m.  Alpha Synuclein As Potential Pathophysiological Marker Of Alzheimer’s
Filippo Baldacci (Italy)

10:15-10:35 a.m.  Retinal Imaging And Dementia: An Overview
Tien Yin Wong (Singapore)

10:35-10:55 a.m.  Mapping Of Alzheimer’s Retinopathy And Predicting Disease Stage
Maya Koronyo-Hamaoui (U.S.)

10:55-11:15 a.m.  Neurofilament Light And Phosphorylated Tau In Blood As AD Biomarkers
Kaj Blennow (Sweden)

11:15-11:40 a.m.  Panel of Session 1 speakers and keynote
Moderator: Donna Wilcock (U.S.)

11:40 a.m.-1 p.m.  LUNCH AND POSTER VIEWING

1-2 p.m.  Lightning Poster Round 1
Moderator: Cassandra Szoeke (AUS)
**Session 2: Novel Biomarkers: Volume 2 (Early Detection)**

**Session Leader:** Simon Laws (AUS)

2:20 p.m. Visualizing Mitochondrial Abnormalities In Alzheimer's Models Using PET

Anna Barron (Singapore)

2:20-2:40 p.m. Using DIAN To Identify And Stage Novel Biomarkers For Alzheimer's Disease

Peter Schofield (AUS)

2:40-3 p.m. Plasma Amyloid Beta Biomarker:
The Potential For Clinical Application

Akinori Nakamura (Japan)

3-3:20 p.m. Plasma Biomarkers For Predicting Amyloid Beta Accumulation And Neurodegeneration In Alzheimer's Disease

Colin Masters (AUS)

3:20-3:40 p.m. Panel of Session 2 speakers

Moderator: Simon Laws (AUS)

3:40-4:10 p.m. BREAK

**Session 3: Therapeutics: State of the Field**

**Session Leader:** Malu Tansey (U.S.)

4:10-4:30 p.m. Ultrasound: Novel Treatment Modality For Neurodegenerative Diseases

Jürgen Götz (AUS)

4:30-4:50 p.m. Use Of Amyloid Imaging In Therapeutic Trials

Victor Villemagne (AUS)

4:50-5:10 p.m. Tau Immunotherapies

Einar Sigurdsson (U.S.)

5:10-5:30 p.m. A Biomarker-Directed Approach To Targeting Inflammation In Alzheimer's Patients

CJ Barnum (U.S.)

5:30-5:50 p.m. Panel of Session 3 speakers and Giulio Pasinetti (U.S.)

Moderator: Malu Tansey (U.S.)

5:50-6 p.m. Close of Day 1

Maria Carrillo (U.S.)

6-7:30 p.m. OPENING RECEPTION

**Thursday, Sept. 26**

8-9 a.m. Rolling registration and breakfast

9-9:10 a.m. Welcome of Day 2 and keynote introduction

Maria Carrillo (U.S.)

9:10-9:40 a.m. Keynote 2: Role of Inflammation in AD/ADRD

Malu Tansey (U.S.)

9:40-10:45 a.m. LIGHTNING POSTER SESSION

Moderator: Claire Sexton (U.S.)

AAIC Satellite Symposium
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45-10:55 a.m.</td>
<td>Dementia Australia</td>
</tr>
<tr>
<td>10:55-11:20 a.m.</td>
<td>BREAK</td>
</tr>
<tr>
<td>10:55-11:20 a.m.</td>
<td>BREAK</td>
</tr>
<tr>
<td><strong>Session 4: Vascular Contributions: Adding the “V” to ATN Framework</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Session Leader:</strong></td>
<td>Charles DeCarli (U.S.)</td>
</tr>
<tr>
<td>11:20-11:40 a.m.</td>
<td>Plasma Exosome-Based Biomarkers Of VCID</td>
</tr>
<tr>
<td>11:40 a.m.-Noon</td>
<td>CSF Biomarkers Of VCID</td>
</tr>
<tr>
<td>Noon-12:20 p.m.</td>
<td>Imaging Based Biomarkers Of VCID</td>
</tr>
<tr>
<td>12:20-12:40 p.m.</td>
<td>Clinical Biomarkers Of VCID</td>
</tr>
<tr>
<td><strong>12:40-1 p.m.</strong></td>
<td>Panel of Session 4 speakers and keynote</td>
</tr>
<tr>
<td><strong>Moderator:</strong></td>
<td>Charles DeCarli (U.S.)</td>
</tr>
<tr>
<td><strong>1-2:15 p.m.</strong></td>
<td>LUNCH AND POSTER VIEWING</td>
</tr>
<tr>
<td>2:15-2:30 p.m.</td>
<td>Alzheimer’s Disease International</td>
</tr>
<tr>
<td><strong>Session 5: Contributing Risk Factors – Genetics and Vascular Contributions</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Session Leader:</strong></td>
<td>Samantha Burnham (AUS)</td>
</tr>
<tr>
<td>2:30-2:50 p.m.</td>
<td>Post-Stroke Cognitive Impairment From A Global Perspectiva: Clinical Characteristics And Risk Factors</td>
</tr>
<tr>
<td>2:50-3:10 p.m.</td>
<td>Cognitive Aging In Urban And Rural India: Contribution Of Vascular Risk Factors</td>
</tr>
<tr>
<td>3:10-3:30 p.m.</td>
<td>Sex Differences And Vascular Risk Factors In Dementia</td>
</tr>
<tr>
<td>3:30-3:50 p.m.</td>
<td>Gene Combinations And AD Risk In AIBL</td>
</tr>
<tr>
<td><strong>3:50-4:15 p.m.</strong></td>
<td>BREAK</td>
</tr>
<tr>
<td><strong>4:15-4:35 p.m.</strong></td>
<td>SINGER: Intervention In Singapore</td>
</tr>
<tr>
<td><strong>4:35-4:55 p.m.</strong></td>
<td>ARROW: Intervention In Australia</td>
</tr>
<tr>
<td><strong>4:55-5:15 p.m.</strong></td>
<td>U.S. POINTER and KHANDLE studies</td>
</tr>
<tr>
<td><strong>5:15-5:40 p.m.</strong></td>
<td>Panel of Session 5 speakers</td>
</tr>
<tr>
<td><strong>Moderator:</strong></td>
<td>Samantha Burnham (AUS)</td>
</tr>
<tr>
<td><strong>5:40-5:45 p.m.</strong></td>
<td>Close of Day 2</td>
</tr>
</tbody>
</table>
**Friday, Sept. 27**

8-8:30 a.m. Breakfast

8:30-8:40 a.m. Opening of Day 3 and keynote introduction Rachel Whitmer (U.S.)

8:40-9:10 a.m. **Keynote 3:**
WHO Guidelines On Risk Reduction Of Cognitive Decline And Dementia: Implications For Researchers And Policymakers Kaarin Anstey (AUS)

**Session 6: Underrepresented Populations/Observational/Pop Studies: Volume 1**
Session Leader: Mary Sano (U.S.)

9:20-9:40 a.m. Late-Life Risk Factors For Cognitive Performance And Decline Around The Globe: The COSMIC Collaboration Darren Lipnicki (AUS)

9:40-10 a.m. Differences In The Biology Of Cognitive Impairment Within A Diverse Cohort Charles DeCarli (U.S.)

10-10:20 a.m. Progress In Aboriginal And Torres Strait Islander Dementia Prevention And Care Research Kate Smith (AUS)

10:20-10:40 a.m. StepUp For Dementia Research: A Dementia Breakthrough, Powered By You Yun-Hee Jeon (AUS)

10:40-11:10 a.m. **BREAK AND CHECKOUT**

**Session 7: Role of Psychogeriatrics in Dementia Care: Volume 2**
Session Leader: Mary Sano (U.S.)

11:10-11:30 a.m. ABCD: The Role Of Psychogeriatrics in Assessment And Better Care For Dementia Henry Brodaty (AUS)

11:30-11:50 a.m. Lifestyle Modification And Disease Stage: What The Practitioner Needs To Know Nicola Lautenschlager (AUS)

11:50 a.m.- 12:10 p.m. Nursing Research Integrating Technology Into Long-Term Care Wendy Moyle (AUS)

12:10-12:35 p.m. Panel: Session 6 and 7 speakers
Moderator: Mary Sano (U.S.)

12:35-12:45 p.m. Closing remarks Maria Carrillo (U.S.)

12:45 p.m. Boxed lunch and departures
Lightning Poster Round Presenters  
Wednesday, Sept. 25  
Moderator: Cassandra Szoeke (AUS)

**Presenters and Topics:**

**Dr. Prita Asih, Australia**  
Elevated Plasma Soluble TREM2 In Elderly Individuals With High Neocortical Amyloid-β Load

**Dr. James Doecke, Australia**  
Exploring CSF Biomarkers That Add Value To CSF Ab42, t-Tau And p-Tau For Correlation With β-Amyloid PET Status

**Dr. Eleanor Drummond, Australia**  
Phosphorylated Tau Interactome In The Human Alzheimer's Disease Brain

**Dr. Dhamidhu Eratne, Australia**  
Neurofilament Light Chain In Psychiatric And Neurodegenerative Disorders: A 'c-Reactive Protein' For The Brain

**Mr. Colin Groot, Netherlands**  
FDG-PET Reveals Distinct Temporal And Spatial Patterns Of Hypometabolism In Cognitively-Defined Subgroups Of Typical Alzheimer’s Disease

**Dr. Kevin Huynh, Australia**  
In-Depth Lipidomic Profiling Of the Australian Imaging Biomarker And Lifestyle Flagship Study Of Aging

**Dr. Louise Lavrencic, Australia**  
Mild Cognitive Impairment In Older Aboriginal Australians

**Dr. Ramon Martinez-Marmol, Australia**  
Inhibition Of PI 3-Kinase p110δ As A New Approach To Protect Against Alzheimer’s Disease

**Dr. Andrew McKinnon, Australia**  
Sleep And Circadian Functioning Relates To White Matter Micro- and Macro-Structure In Older Adults With A Lifetime History Of Depression

**Dr. Peter van Wijngaarden, Australia**  
A Hyperspectral Retinal Imaging Biomarker Of Alzheimer's Disease

**Mr. Robert Williams, Australia**  
The Use of Phantom Measurement To Harmonise Image Reconstruction In Florbetapir PET
Lightning Poster Round Presenters
Thursday, Sept. 26
Moderator: Claire Sexton (U.S./U.K.)

Presenters and Topics:

Ms. Karissa Barthelson, Australia
Identifying Early Molecular Changes Underlying Familial Alzheimer’s Disease Due To Mutations In SORL1

Dr. Pierrick Bourgeat, Australia
Comparing Aβ-Amyloid Positivity Thresholds Using Suvr And Centiloid Across Tracers

Dr. Zac Chatterton, Australia
Peripheral Monitoring Of Neurodegeneration Using Cell-Free DNA Methylation

Dr. Carol Dobson-Stone, Australia
Identification Of A Novel Gene Causing Frontotemporal Dementia – Amyotrophic Lateral Sclerosis

Dr. R.M. Damian Holsinger, Australia
Fecal Microbiota Transplantation Improves Cognition And Significantly Reduces Amyloid Pathology In 5XFAD Alzheimer's Mice

Dr. Woojin Kim Australia
Analysis Of Frontotemporal Dementia Serum Using Lipidomics Technology

Dr. Michelle Lupton, Australia
Genetic Risk Prediction For Alzheimer's Disease And Association With Baseline Measures In The PISA Study

Dr. Morgan Newman, Australia
Biased Allele Expression And Loss Of Hypoxia Response In A Zebrafish Model Of Familial Alzheimer's Disease

Dr. Giulio Pasinetti, United States
Inhibition Of Brain Innate Immunity As Novel Therapeutic Approach In Alzheimer’s Disease To Attenuate Psychological Stress Induced Dementia

Mr. Anishchal Pratap, Australia
Altered Metabolic Characteristics Of Activated Astrocytes In The 5XFAD Mouse Model Of Alzheimer's Disease

Dr. Jonathan Teo, Australia
Loss Of Sphingosine Kinase 2 In Alzheimer's Disease Impedes Amyloid Deposition But Enhances Hippocampal Volume Loss And Demyelination

Dr. Giuseppe Verdile, Australia
Relevance Of A Truncated Presenilin 2 Transcript To Alzheimer's Disease And Neurodegeneration